Amjevita (Adalimumab-atto) for Psoriasis

Overview
Amjevita is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat active psoriatic arthritis and moderate to severe chronic plaque psoriasis in adults. Amjevita may be referred to by its drug name, adalimumab-atto. Amjevita is a biosimilar of Humira. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.

Amjevita is considered a biologic drug. Amjevita is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Amjevita is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

How do I take it?
Amjevita is administered as a subcutaneous injection every week or every other week.

Amjevita is available as a single-use, prefilled auto-injector or syringe.

Side effects
The FDA-approved label for Amjevita lists common side effects including infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.

Rare but serious side effects listed for Amjevita can include severe infections, heart failure, increased risk for certain types of cancer, lupus-like syndrome, invasive fungal infections, severe allergic reactions, hepatitis B reactivation, and the development of demyelinating conditions such as multiple sclerosis.

For more details about this treatment, visit:

Amjevita — Amgen
https://www.pi.amgen.com/~/media/amgen/reposito...